



Developing a Chlamydia Trachomatis vaccine

Fact Sheet

Project Information

TracVac

Grant agreement ID: 733373

[Project website](#)

DOI

[10.3030/733373](https://doi.org/10.3030/733373)

Project closed

EC signature date

22 February 2017

Start date

1 March 2017

End date

28 February 2022

Funded under

SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost

€ 6 674 497,50

EU contribution

€ 6 674 497,50

Coordinated by

STATENS SERUM INSTITUT



Denmark

Objective

The TRACVAC Consortium will eliminate the global problem of blinding trachoma through the development of a vaccine. Our strategy of the project will eliminate two important bottlenecks for the development of a trachoma vaccine 1) The lack of neutralizing antibody responses to vaccine preparations based on MOMP 2) The challenge of inducing vaccine promoted sustained local ocular IgA.

TRACVAC has two main objectives. The first main objective is to generate a vaccine that protect against the bacterial strains causing ocular Chlamydia trachomatis infections. To accomplish this we first select naturally protected individuals from high

endemic regions and identify all neutralizing epitopes from the major outer membrane antigen (MOMP) of *Chlamydia trachomatis* through the unique combination of the B cell cloning and high density array technology. The epitopes will be produced as vaccines through the use of the immuno-repeat technology that is known to increase the quality and quantity of the vaccine promoted response. The second main objective is to develop an immunization protocol for optimal ocular mucosal immunity. To do this we will establish an ocular non-human primate (NHP) challenge model and use this to test different prime boost vaccination strategies for ocular responses and protection against challenge. We will subsequently test the best strategy in a clinical phase I evaluation of a trachoma vaccine based on a immuno-repeat construct targeting serovar B. This will provide early human proof of concept both for the immuno-repeat technology and the prime boost strategy for ocular IgA. In summary, TRACVAC will deliver a final vaccine candidate targeting the main ocular serovars and a vaccine protocol ready to enter a clinical phase I trial.

TRACVAC is highly relevant for the topic (Vaccine development for malaria and/or neglected infectious diseases), as the aim is to accelerate vaccine development against the neglected infectious disease Trachoma.

Fields of science (EuroSciVoc)

[medical and health sciences](#) > [health sciences](#) > [infectious diseases](#) > **[malaria](#)**

[medical and health sciences](#) > [health sciences](#) > **[public health](#)**

[medical and health sciences](#) > [basic medicine](#) > [immunology](#) > **[immunisation](#)**

[medical and health sciences](#) > [basic medicine](#) > [pharmacology and pharmacy](#) > [pharmaceutical drugs](#) > **[vaccines](#)**

[medical and health sciences](#) > [basic medicine](#) > [pharmacology and pharmacy](#) > [pharmaceutical drugs](#) > **[antibiotics](#)**



Keywords

[Clinical trial](#)

[Infectious disease](#)

[Bacteria](#)

[Immunology](#)

[Chlamydia](#)

[Trachoma](#)

Programme(s)

Topic(s)

[SC1-PM-06-2016 - Vaccine development for malaria and/or neglected infectious diseases](#)

Call for proposal

[H2020-SC1-2016-2017](#)

[See other projects for this call](#)

Sub call

H2020-SC1-2016-RTD

Funding Scheme

[RIA - Research and Innovation action](#)

Coordinator



STATENS SERUM INSTITUT

Net EU contribution

€ 2 099 187,50

Total cost

€ 2 099 187,50

Address

**ARTILLERIVEJ 5
2300 København S**

 **Denmark** 

Region

Danmark > Hovedstaden > Byen København

Activity type

Research Organisations

Links

- [Contact the organisation](#)
- [Website](#)
- [Participation in EU R&I programmes](#)
- [HORIZON collaboration network](#)

Participants (3)



LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER

United Kingdom
Net EU contribution
€ 1 012 655,75

Address
KEPPEL STREET
WC1E 7HT London

Region
London > Inner London — West > Camden and City of London

Activity type
Higher or Secondary Education Establishments

- Links
- [Contact the organisation](#)
 - [Website](#)
 - [Participation in EU R&I programmes](#)
 - [HORIZON collaboration network](#)

Total cost
€ 1 012 655,75



COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

France
Net EU contribution
€ 1 945 433,75

Address
RUE LEBLANC 25
75015 PARIS 15

Region
Ile-de-France > Ile-de-France > Paris

Activity type

Research Organisations

Links

[Contact the organisation](#)  [Website](#) 

[Participation in EU R&I programmes](#) 

[HORIZON collaboration network](#) 

Total cost

€ 1 945 433,75



IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

 United Kingdom

Net EU contribution

€ 1 617 220,50

Address

**SOUTH KENSINGTON CAMPUS EXHIBITION ROAD
SW7 2AZ LONDON** 

Region

London > Inner London — West > Westminster

Activity type

Higher or Secondary Education Establishments

Links

[Contact the organisation](#)  [Website](#) 

[Participation in EU R&I programmes](#) 

[HORIZON collaboration network](#) 

Total cost

€ 1 617 220,50

Last update: 8 December 2023

Permalink: <https://cordis.europa.eu/project/id/733373>

European Union, 2025